Emil Johansson | Senior Scientist, Neurodegeneration Program Lead
La Jolla Institute for Allergy and Immunology

Emil Johansson, Senior Scientist, Neurodegeneration Program Lead, La Jolla Institute for Allergy and Immunology

Dr. Johansson earned his Ph.D. in Biomedical Sciences from Lund University (Sweden) in 2023, where he studied virus–host interactions in HIV-1 and HIV-2 infections. In 2023, he joined Professor Alessandro Sette’s laboratory at the La Jolla Institute for Immunology, where he combines computational and experimental approaches to characterize antigen-specific T cells. Building on this expertise, he investigates the role of autoreactive T cells in neurodegenerative diseases, with the aim of informing new diagnostic strategies and therapeutic interventions.

Appearances:



Pre-Congress Workshops - Monday 30th March @ 10:00

CHRONIC DISEASE, AUTOIMMUNITY & THE VIROME WORKSHOP (AM)

CHRONIC DISEASE, AUTOIMMUNITY & THE VIROMERoom 204C

Exploring the drivers and development of vaccines against non-infectious disease targets. 

10am Chair’s opening remarks: Michael Caldwell, Meharry Medical College

10:10am Opening presentation: Virome Discovery: Mapping the Invisible Drivers of DiseaseSpeaker TBC

10:30 Uncovering the Immune Landscape of Autoimmune Disease: From Parkinsons to ALSDr Emil Johansson, Senior Scientist, Neurodegeneration Program Lead, LaJolla Institute for Immunology

10:50 Clinical Development of a TLR4 Agonist in Phase 2 Trials for Allergic RhinitisDr Shannon Miller, VP of Operations, Inimmune

11:10 Accelerating Development of Vaccines for Prevention and Control of Alzheimer’s Disease:  The Alzheimer’s Vaccine InitiativeDr Wayne Koff, Managing Partner, Next Frontier Advisors

11:30 The shingles vaccine and dementia: A causal relationship?Dr Pascal Geldsetzer, Assistant Professor of Medicine, Stanford University

11.50am – 12:50pm Panel: Adjuvants and Immunity: Exploring Systemic Benefits Beyond Zoster- Beyond Shingles: Explore emerging data linking zoster vaccines to reduced risks of cardiovascular disease and Alzheimer’s.- Immunological Insights: Discuss how zoster vaccines adjuvant systems may drive systemic immune benefits beyond zoster prevention- Correlates of Protection: Identify immune markers that may explain long-term protection and -potential cross-disease benefits.- Public Health Implications: Debate whether zoster vaccines should be recommended earlier in life for chronic disease prevention.- Future Research: Outline next steps for validating these findings and applying the model to other latent viruses like EBV.Moderator: Jay Evans, Chief Scientific and Strategy Officer, InimmuneDr Bali Pulendran, Professor, Director, Institute for Immunity, Transplantation and Infection, Stanford University School of MedicineDr Pascal Geldsetzer, Assistant Professor of Medicine, Stanford UniversityDr Kouji Kobiyama, UCSD *TBC

last published: 11/Mar/26 19:15 GMT

back to speakers